Try our beta test site

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

This study has suspended participant recruitment.
(Scheduled interim monitoring)
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01811212
First received: March 12, 2013
Last updated: January 31, 2017
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Study Completion Date: No date given
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)